ONCOCROSS
ONCOCROSS
Industry:
Biotechnology Pharmaceutical
Founded:
2015-06-22
Address:
Mapo, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.oncocross.com
Total Employee:
1+
Status:
Active
Contact:
02-867-9967
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Global Site Tag Mobile Non Scaleable Content Euro Google Analytics 4
Similar Organizations
Takeda Oncology
Takeda Oncology is a leading biopharmaceutical company.
Current Employees Featured
Founder
Official Site Inspections
http://www.oncocross.com Semrush global rank: 7.45 M Semrush visits lastest month: 492
- Host name: ec2-52-79-216-114.ap-northeast-2.compute.amazonaws.com
- IP address: 52.79.216.114
- Location: Incheon South Korea
- Latitude: 37.4562
- Longitude: 126.7288
- Timezone: Asia/Seoul
- Postal: 21539
More informations about "Oncocross"
Oncocross - Crunchbase Company Profile
Oncocross may be growing as it has initiated a technical evaluation process, which could indicate an expansion of its operations or development of new products. The company has also secured funding, as evidenced by the …See details»
Mission - ONCOCROSS : we make drugs works
Oncocross is developing treatments for cancers, rare diseases, and intractable diseases, thereby contributing to a healthier world. Unrivaled Database Quality. Our analysis is based on …See details»
Oncocross Company Profile 2024: Valuation, …
Oncocross General Information Description. Developer of cancer drugs intended to use artificial intelligence-based methods to accelerate drug development. The company's platform uses gene expression patterns to create new medicines at …See details»
Platform - ONCOCROSS : we make drugs works
Platform - We make drugs work. We value nothing more important than life. Through our AI technology, we strive to develop drugs for every single patient suffering from intractable disease.See details»
Oncocross - Funding, Financials, Valuation & Investors
Oncocross has raised a total of. obfuscated. in funding over 3 rounds. Their latest funding was raised on Mar 4, 2021 from a Corporate Round round. Oncocross is funded by 15 investors. …See details»
Oncocross Co., Ltd. - Drug pipelines, Patents, Clinical trials …
Oncocross announced that it had demonstrated the objective safety and pharmacokinetic pro OC514 through the safety evaluation and the analysis of pharmacokinetic parameters …See details»
Oncocross - Products, Competitors, Financials, …
Oncocross develops drugs, with a particular focus on leveraging artificial intelligence (AI) technology, while working in the biotech industry. The company's main services involve the …See details»
Oncocross - Company info. interviews, news
While our AI technology offers platform to minimize cost, time, and risk of clinical failure for drug candidates, our desire to provide alternative cost competitive treatments for patients with rare …See details»
Oncocross Expands Collaboration with JW Pharmaceutical …
SEOUL, South Korea, May 27, 2024--Oncocross, a Seoul-based AI drug discovery and development biotech, announced on May 22nd that it has signed a joint research agreement …See details»
Oncocross - Recent News & Activity - Crunchbase
Oct 27, 2023 Organization. Oncocross . Connect to CRM . Save . Go back to Oncocross's Signals & News . Recent News & Activity. Edit Recent News & Activity Section. Number of …See details»
History - ONCOCROSS : we make drugs works
MOU with Korea Research Institute of Chemical Technology. Selected in the Government Sponsored Cancer Project. History - We make drugs work. We value nothing more important …See details»
Oncocross Completes Phase I Global Clinical Trial of …
May 10, 2023 Oncocross Co., Ltd. Daniel Kim +82-2-867-9967 [email protected] Release Summary Oncocross, an AI drug discovery and development biotech, completed the …See details»
Oncocross Completes Phase 1 Global Clinical Trial of …
May 11, 2023 SEOUL--(Korea Newswire)--Oncocross, a Seoul-based AI drug discovery and development biotech, announced the completion of phase 1 global clinical trial of OC514, a …See details»
OC-211 - Drug Targets, Indications, Patents - Synapse
6 days ago OC-211: a KRAS gene inhibitors Drug, Initially developed by Oncocross Co., Ltd., Mechanism: KRAS gene inhibitors. Biomedical products. Data. Feature. Plans. Sign Up for …See details»
Partnership - ONCOCROSS : we make drugs works
Oncocross New Drug Development Pipelines. We are developing pipelines on cancers, rare diseases, intractable diseases, and metabolic diseases on our own as well as through …See details»
Oncocross Completes Phase I Global Clinical Trial of …
11 May 2023. Oncocross, a Seoul-based AI drug discovery and development biotech, announced the completion of phase 1 global clinical trial of OC514, a treatment targeting sarcopenia and …See details»
Oncocross - Contacts, Employees, Board Members, …
Organization. Oncocross . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. Oncocross has 1 …See details»
Oncocross Begins Phase I Clinical Trial of AI-Developed …
Feb 28, 2022 SEOUL--(Korea Newswire)--Oncocross, an AI-based drug development biotech, announced that it initiated a phase I global clinical trial for ‘OC514’ targeting muscular …See details»